Physician profile
Michael J Bergstein
NPI 1679512727
$7,999.17
in general payments reported to CMS, 2019-2025
35 companies · $844 in 2025
The $844 reported for 2025 was more than what 82% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,587 · 2020: $676 · 2021: $537 · 2022: $1,384 · 2023: $1,055 · 2024: $916 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $1,984.20 | 2019-2022 | |
| Optinose US, INC. | $1,168.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,006.12 | 2019-2024 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $452.82 | 2020-2023 | |
| Aerin Medical INC. | $437.79 | 2019-2025 | |
| Pentax of America, INC. | $355.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $349.97 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $311.66 | 2020-2024 | Cuvitru, Takhzyro |
| Neurent Medical Limited | $227.44 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Regeneron Healthcare Solutions, INC. | $226.48 | 2019-2023 | Dupixent |
| Pharming Healthcare, INC. | $165.96 | 2019-2023 | Ruconest |
| Astrazeneca Pharmaceuticals Lp | $153.13 | 2019-2025 | Tezspire |
| Csl Behring | $134.12 | 2019-2025 | Andembry, Haegarda |
| Stryker Corporation | $133.08 | 2019-2025 | Audion Et Dilation System, Clarifix, Scopis Ent |
| Hikma Pharmaceuticals USA | $127.57 | 2023-2024 | Ryaltris |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $112.73 | 2021-2023 | Orladeyo |
| Kaleo, INC. | $91.85 | 2021-2024 | Auvi-Q |
| Medtronic, INC. | $75.56 | 2024 | Propel |
| Pfizer INC. | $71.33 | 2020-2022 | |
| Smith+Nephew, INC. | $56.98 | 2023-2025 | Coblation, Halo, Tula |
| Integra Lifesciences Corporation | $45.72 | 2024 | Inspira Air, Acclarent Aera, Trudi Probe |
| Merck Sharp & Dohme LLC | $36.53 | 2023 | |
| Krystal Biotech INC | $30.10 | 2024 | Vyjuvek |
| Ars Pharmaceuticals Operations, INC. | $26.91 | 2025 | Neffy |
| Lilly USA, LLC | $25.85 | 2025 | Zepbound |
| Blueprint Medicines Corporation | $24.51 | 2023 | Ayvakit |
| Phathom Pharmaceuticals, INC. | $24.38 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $22.81 | 2025 | Xhance |
| Amgen INC. | $21.45 | 2025 | Tezspire |
| Inspire Medical Systems, INC. | $19.01 | 2024 | Inspire |
| Biocryst Pharmaceuticals, INC. | $18.42 | 2020 | |
| Horizon Therapeutics Plc | $18.05 | 2019 | |
| Shire North American Group INC | $17.59 | 2019 | |
| Alk-Abello, INC | $13.51 | 2019 | |
| Circassia INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bergstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.